The Potential for Therapeutic Misconception in Pulmonary Arterial Hypertension Clinical Trials: A Case-Based Discussion

Advances in Pulmonary Hypertension

¹ 

关键词: Cardiology;    Rheumatology;    Psychosocial Issues;    Lifestyle Issues;    Social Work;    WHO Group 1- Pulmonary Arterial Hypertension;    PH Medications;    Surgical Interventions;    symptoms;    Gender;    PH;    Research;    Exercise;    Genetic Testing;    Associated Diseases;    Connective Tissue Diseases;    Scleroderma;    Oral therapy;    IV therapy;    Phosphodiesterase Inhibitors (PDE-5 Inhibitors);    contraindications;    Diuretics;    exercise hemodynamic testing;    Inflammation;    endothelial dysfunction;    tricuspid regurgitation;    Testosterone;    Ethics;    Drug development;    clinical trial;    clinical trial endpoints;    PHAROS;    pre-clinical research;    Education;    CME;    Classification;    Epidemiology;   

DOI  :  

学科分类：医学（综合）

来源: Pulmonary Hypertension Association

【 摘 要 】

The 2 most common causes of death after the first transplant year include bronchiolitis obliterans and infection.50 Long-term success of lung transplantation is limited by chronic allograft dysfunction—thought primarily due to chronic allograft rejection. This injury has been characterized by scar formation and fibrosis of the small airways and defined as bronchiolitis obliterans.51 The diagnosis of bronchiolitis obliterans requires a histopathologic specimen that includes the small- to medium-sized airways. However, transbronchial biopsies are insensitive for the diagnosis of bronchiolitis obliterans, since mostly alveolar tissues are obtained and bronchioles are infrequently sampled. The ISHLT developed a reproducible and reliable surrogate marker for bronchiolitis obliterans that utilizes declining FEV1, the bronchiolitis obliterans syndrome.52 The system has been widely adopted and validated as a useful surrogate for histological bronchiolitis obliterans.

【 授权许可】

All Rights reserved